Abstract:
:The recent introduction of new microarray expression technologies and the further development of established platforms ensure that the researcher is presented with a range of options for performing an experiment. Whilst this has opened up the possibilities for future applications, such as exon-specific arrays, increased sample throughput and 'chromatin immunoprecipitation (ChIP) on chip' experiments, the initial decision processes and experiment planning are made more difficult. This review will give an overview of the various technologies that are available to perform a microarray expression experiment, from the initial planning stages through to the final data analysis. Both practical aspects and data analysis options will be considered. The relative advantages and disadvantages will be discussed with insights provided for future directions of the technology.
journal_name
Pharmacogenomicsjournal_title
Pharmacogenomicsauthors
Elvidge Gdoi
10.2217/14622416.7.1.123keywords:
subject
Has Abstractpub_date
2006-01-01 00:00:00pages
123-34issue
1eissn
1462-2416issn
1744-8042journal_volume
7pub_type
杂志文章,评审相关文献
PHARMACOGENOMICS文献大全abstract:AIM:Based on previous pharmacogenetic findings, we investigated the possible association between SULT4A1-1 haplotype and antipsychotic treatment response. MATERIALS & METHODS:Using Mixed Model Repeated Measures, we tested the relationship between SULT4A1-1 status (+carrier, -noncarrier) and clinical improvement (in Po...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.14.105
更新日期:2014-01-01 00:00:00
abstract:BACKGROUND:Prednisolone is a potent anti-inflammatory glucocorticoid (GC) but chronic use is hampered by metabolic side effects. Little is known about the long-term effects of GCs on gene-expression in vivo during inflammation. AIM:Identify gene signatures underlying prednisolone-induced metabolic side effects in a co...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.14.3
更新日期:2014-04-01 00:00:00
abstract:AIM:To determine diagnostic accuracy of HLA-B*57:01 testing for prediction of abacavir-induced hypersensitivity and to quantify the clinical benefit of pretreatment screening through a meta-analytic review of published studies. METHODS:A comprehensive search was performed up to June 2013. The methodological quality of...
journal_title:Pharmacogenomics
pub_type: 杂志文章,meta分析
doi:10.2217/pgs.14.52
更新日期:2014-05-01 00:00:00
abstract:INTRODUCTION:Warfarin is a widely prescribed, efficacious oral anticoagulant. S-warfarin, the more active form, is metabolized by the cytochrome P450 (CYP)2C9 enzyme. The aim was to evaluate the influence of two CYP2C9 functional polymorphisms (*2 and *3) on warfarin dose in African-Americans, an unstudied population a...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/14622416.8.3.217
更新日期:2007-03-01 00:00:00
abstract::Recent research highlighted the large extent of rare variants in pharmacogenes and, on this basis, it was estimated that rare variants account for 30-40% of the functional variability in pharmacogenes. It has been proposed that comprehensive next-generation sequencing (NGS)-based sequencing of pharmacogenes could soon...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/pgs-2016-0023
更新日期:2016-06-01 00:00:00
abstract::Insulin-sensitizer treatment with metformin is common in polycystic ovary syndrome (PCOS). OCT alleles were investigated in PCOS patients to identify genetic 'bad responders' and 'nonresponders' to metformin including their possible effects on glucose metabolism without treatment. We genotyped eight SNPs in OCT1, OCT2...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.13.223
更新日期:2014-02-01 00:00:00
abstract:AIMS:The identification of predictive markers of response to chemoradiotherapy treatment remains a promising approach for patient management in order to obtain the best response with minor side effects. Initially, we investigated whether the analysis of several markers previously studied and others not yet evaluated co...
journal_title:Pharmacogenomics
pub_type: 临床试验,杂志文章
doi:10.2217/pgs.10.51
更新日期:2010-06-01 00:00:00
abstract::Drugs used to treat psychiatric disorders, even when taken as directed, fail to provide adequate relief for a sizeable proportion of patients. Despite our advancements in understanding human genetics and development of high-throughput tools to probe variation, pharmacogenomics has yielded marginal ability to predict d...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/pgs-2017-0104
更新日期:2017-10-01 00:00:00
abstract:AIM:We aimed to understand consent practices for pharmacogenetic (PGx) testing. METHODS:We conducted a literature review and analysis of consent forms from clinical laboratories offering PGx testing. RESULTS:Our review of the literature shows a lack of consensus about the need for and type of informed consent for PGx...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/pgs-2016-0039
更新日期:2016-09-01 00:00:00
abstract::Large interindividual variation in efficacy and adverse effects of anti-epileptic therapy presents opportunities and challenges in pharmacogenomics. Although the first true association of genetic polymorphism in drug-metabolizing enzymes with anti-epileptic drug dose was reported 10 years ago, most of the findings hav...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/pgs.09.34
更新日期:2009-05-01 00:00:00
abstract:AIM: HLA-B*15:02 screening should be performed to prevent antiepileptic drug induced severe cutaneous adverse reactions in populations of Asian origin. This study aimed to develop fast and reliable HLA-B*15:02 genotyping method and to investigate the distribution of HLA-B*15:02 in different Chinese ethnicities. MATERI...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs-2017-0041
更新日期:2017-06-01 00:00:00
abstract::Recently, the USA FDA has made a labeling change to the drug information contained in carbamazepine. Owing to recent data implicating the HLA allele B*1502 as a marker for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese, the FDA recommends genotyping all Asians for the alle...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/14622416.9.10.1543
更新日期:2008-10-01 00:00:00
abstract:AIM:No definite factors predict blood pressure response to angiotensin-converting enzyme-inhibitors. The aim of this study was to test the association of gene polymorphisms of the renin-angiotensin-aldosterone system with essential hypertension and anthropometric variables, intermediate phenotypes and gene polymorphism...
journal_title:Pharmacogenomics
pub_type: 杂志文章,随机对照试验
doi:10.2217/14622416.9.10.1419
更新日期:2008-10-01 00:00:00
abstract::DxS is a pharmacogenomics business operating at the interface between genetic diagnostics and the pharmaceutical industry. The company strategy is to enable pharmacogenomics by the provision of genetic analysis services to the healthcare sector. The services provide support for drug discovery, drug development and als...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.1517/phgs.4.1.97.22580
更新日期:2003-01-01 00:00:00
abstract::The value of high-throughput genomic research is dramatically enhanced by association with key patient data. These data are generally available but of disparate quality and not typically directly associated. A system that could bring these disparate data sources into a common resource connected with functional genomic...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.1517/14622416.3.5.651
更新日期:2002-09-01 00:00:00
abstract::Aim: The influence of variants in pharmacokinetics-related genes on long-term exposure to tacrolimus (TAC)-based therapy and clinical outcomes was investigated. Patients & methods: Brazilian kidney recipients were treated with TAC combined with everolimus (n = 178) or mycophenolate sodium (n = 97). The variants in CYP...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs-2019-0120
更新日期:2020-01-01 00:00:00
abstract:BACKGROUND:Clobazam-induced adverse reactions have been reported in cases with CYP2C19 defective allele(s). However, the relevance of the CYP2C19 genotypes to clobazam therapy remains to be clarified. METHODS:The association between CYP2C19 genotypes and the antiepileptic and adverse effects of clobazam was retrospect...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/14622416.9.5.527
更新日期:2008-05-01 00:00:00
abstract::The aim of this work was to determine the VKORC1 haplotype profile in healthy Hungarian and Roma population samples, and to compare our data with other selected populations. Using haplotype tagging SNPs (G-1639A, G9041A and C6009T), we characterized Hungarian (n = 510) and Roma (n = 451) population samples with regard...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.09.46
更新日期:2009-06-01 00:00:00
abstract::Recent years have seen great advances in our understanding of genetic contributors to drug response. Drug discovery and development around targeted genetic (somatic) mutations has led to a number of new drugs with genetic indications, particularly for the treatment of cancers. Our knowledge of genetic contributors to ...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.13.52
更新日期:2013-05-01 00:00:00
abstract::EVALUATION OF: Ahuja SK, Kulkarni H, Catano G et al.: CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat. Med. 14(4), 413-420 (2008). It is widely accepted that the effect of highly active antiretroviral therapy (HAART) varies widely among HIV...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/14622416.9.9.1347
更新日期:2008-09-01 00:00:00
abstract:AIM:The present study introduces a simple method for CYP2D6 genotyping that not only determines the heterozygous or homozygous deletions and duplications, but also distinguishes tandem hybrids. MATERIALS & METHODS:Using two commercially available methods, 49 Korean male subjects were genotyped for CYP2D6. The Affymetr...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.12.58
更新日期:2012-06-01 00:00:00
abstract:AIMS:Survival and response rates in metastatic colorectal cancer remain poor, despite advances in drug development. There is increasing evidence to suggest that gender-specific differences may contribute to poor clinical outcome. We tested the hypothesis that genomic profiling of metastatic colorectal cancer is depende...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.10.163
更新日期:2011-01-01 00:00:00
abstract::The extent of genetic variation found in drug metabolism genes and its contribution to interindividual variation in response to medication remains incompletely understood. To better determine the identity and frequency of variation in 11 phase I drug metabolism genes, the exons and flanking intronic regions of the cyt...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.1517/14622416.5.7.895
更新日期:2004-10-01 00:00:00
abstract::Evaluation of: Woynarowski JM, Krugliak M, Ginsburg H: Pharmacogenomic analyses of targeting the AT-rich malaria parasite genome with AT-specific alkylating drugs. Mol. Biochem. Parasitol. 154(1), 70-81 (2007) [1] . The sequencing of the malaria genome sought to expose the parasite's ability to cause disease and ident...
journal_title:Pharmacogenomics
pub_type: 评论,杂志文章
doi:10.2217/14622416.8.9.1267
更新日期:2007-09-01 00:00:00
abstract::Pharmacogenomic analyses will become crucial to predict patients' toxicity to treatment and will also help to predict the tumor response. Processes of drug metabolism, drug efflux, DNA-repair and characteristics of drug targets are critical checkpoints of drug efficacy. These crucial pathways for drug action have been...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.1517/phgs.4.6.767.22825
更新日期:2003-11-01 00:00:00
abstract::ALK was first reported in 1994 as a translocation in anaplastic large cell lymphoma and then described with different abnormalities in a number of tumors. Recently, a shortly accumulated biomedical research clarified the numerous biological processes underlying its ability to support cancer development, growth and pro...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs-2016-0166
更新日期:2017-02-01 00:00:00
abstract:AIM:The activity of several key enzymes involved in the metabolism of many drugs is subject to change closely related to the age of patients. This possibility must also be considered in the case of tacrolimus, the most important calcineurins inhibitor, which is widely used in pediatric kidney transplantation. As well a...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.15.18
更新日期:2015-01-01 00:00:00
abstract:AIMS:The current study investigates whether or not functional polymorphisms in the ATP-binding cassette transporter gene ABCG2 might affect gefitinib activity and/or toxicity in non-small-cell lung cancer (NSCLC) patients. MATERIALS & METHODS:Towards this end, ABCG2 polymorphisms and expression were assessed in DNA an...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.10.172
更新日期:2011-02-01 00:00:00
abstract:INTRODUCTION:Polymorphic alleles in the human genome have been identified as affecting numerous drug responses. Currently, genotyping of all patients before starting a drug regimen is impractical. Since many polymorphisms occur at varying rates in different racial groups, we investigated whether a patient's race could ...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/14622416.9.11.1639
更新日期:2008-11-01 00:00:00
abstract::The number of reports investigating disease susceptibility based on the carriage of low-penetrance, high-frequency polymorphisms has steadily increased over the last years. Evidence based on meta-analyses of individual case-control studies is accumulating, defining specific individual variations in disease susceptibil...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.1517/phgs.5.1.57.25687
更新日期:2004-01-01 00:00:00